Skip to main content
TipRanks
Go Ultimate75% OFF

Organogenesis Holdings (2PQ) Q3 2026 Earnings Report

1 Followers

DE:2PQ Q3 2026 EPS Results

Actual EPS
-EUR 0.22
Consensus EPS
-EUR 0.16
Beat/Miss
Missed by -EUR 0.07
One Year Ago EPS
EUR 0.11

DE:2PQ Q3 2026 Revenue Results

Actual Revenue
EUR 40.96M
Expected Revenue
EUR 46.95M
Beat/Miss
Missed by -EUR 5.99M
YoY Revenue Growth
-69.87%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:2PQ Upcoming Earnings

Organogenesis Holdings's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:2PQ Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-1.37%|
Earnings Call Sentiment|Neutral

The call presented a mixed outlook. Organogenesis reported severe year-over-year revenue declines, losses, lower gross margin, reduced full-year revenue guidance, and a delayed Amnuvx regulatory timeline. However, sequential revenue improved, market share expanded across multiple products, clinical evidence strengthened, expenses were materially reduced, and management expects continued market recovery and improving adjusted EBITDA. The positive strategic and sequential trends offset, but do not eliminate, the significant current-period financial and regulatory challenges.

Company Guidance

For 2026, the company expects to see sequential improvement in its revenue trends in the third and fourth quarters and a more measured recovery in the overall operating environment in the second half of 2026, with total net revenue of $179 million-$200 million, representing a decline in the range of 65%-68% year over year, versus prior guidance of 62%-68%; Advanced Wound Care sales are expected in the range of $151 million-$171 million, Surgical & Sports Medicine sales in the range of $26 million-$27 million, and grant income of $1.9 million. Updated guidance assumes improving quarterly adjusted EBITDA performance on a sequential basis, resulting in more than a 60% reduction in adjusted EBITDA loss in the second half of 2026 as compared to the first half of 2026 at the low end of the range, and more than 80% reduction in adjusted EBITDA loss in the second half of 2026 as compared to the first half of 2026, including the expectation of positive adjusted EBITDA generation in the fourth quarter. Cost reductions are expected to result in a total reduction in operating expense of approximately $45 million, of which approximately $32 million is related to restructuring; Amnuvx remediation is expected to be completed by September 30th, 2027, with an $8 million total spend, a $4 million pull forward, about 25% of that done in 2026, and the remainder in 2027 through the third quarter.

  • Sequential Revenue ImprovementTotal revenue increased 6% quarter-over-quarter in the third quarter, with Advanced Wound Care sales up 6% and Surgical & Sports Medicine sales up 10%. Management said the operating environment improved from the second quarter, particularly as clinician confusion declined.
  • Market Share Gains Across the PortfolioOrganogenesis reported that its market share increased more than 30% versus Q1 and at a rate more than double that of major established competitive portfolios. Apligraf, PuraPly AM, Affinity, and NuShield all demonstrated meaningful improvement, and the company reported treating more patients with increasing utilization of its skin substitutes.
  • Competitive Position StrengthenedManagement said distributor-driven competitors, high-priced amniotic players, and companies engaged in fraudulent practices have been substantially reduced, while many remaining players are diversifying away from wound care or exiting the category. The company said customers are increasingly selecting products and partners based on efficacy, outcomes, and evidence.
  • PuraPly AM Clinical Evidence ExpandedThe PREPARE prospective multicenter randomized controlled trial achieved its primary endpoints. Results published in the Journal of Wound Care showed statistically significant improvements in wound closure at 12 weeks for patients treated with PuraPly AM plus standard of care for non-healing diabetic foot ulcers. Organogenesis said its PuraPly AM evidence base spans more than 23,000 patients, including comparative effectiveness research and a large patient registry.
  • Amnuvx BLA Progressed to FDA ReviewThe company completed its Amnuvx BLA submission in April 2026, and the FDA accepted it for review in June 2026. Management described Amnuvx as a potential non-surgical, single-injection biologic for knee osteoarthritis and said its commitment to pursuing the BLA remains unchanged.
  • Significant Expense ReductionOperating expenses declined 42% year-over-year to $75.0 million, while non-GAAP operating expenses excluding cost of goods sold declined 44% to $53.0 million. The company reported a $43% reduction in SG&A expenses of $34.7 million and a 40% reduction in research and development expenses of $5.3 million. March and June restructurings and additional cost reductions are expected to reduce operating expenses by approximately $45 million in 2026, including approximately $32 million related to restructuring.
  • Expected Improvement in Adjusted EBITDAThe updated outlook assumes more than a 60% reduction in adjusted EBITDA loss in the second half of 2026 versus the first half at the low end of the range, and more than an 80% reduction at the high end, including the expectation of positive adjusted EBITDA in the fourth quarter. Management said adjusted EBITDA improved by approximately $12 million-$13 million each quarter.
  • Debt-Free Balance Sheet and Near-Term FundingAs of September 30, 2026, the company had $26.9 million in cash, cash equivalents, and restricted cash, with no outstanding debt obligations. Management said cash on hand, other working capital, and net cash flows from product sales are expected to fund operating expenses and capital expenditures for at least the next 12 months.
  • Continued Investment in Evidence and CapacityOrganogenesis said it is increasing its focus on clinical evidence and new published studies, continuing the Amnuvx strategic initiative, and evaluating financing strategies to accelerate Amnuvx commercialization and enhance capacity and efficiencies at the Smithfield facility.
  • Management Sees the Market Moving Past Its BottomManagement stated that the market has clearly bottomed out and that it is seeing improvement in market expansion. It expects low-cost inventory from companies that have exited the space to be substantially cleared by the end of the year and said the market could expand at a double-digit rate once that inventory has moved through the system.

DE:2PQ Earnings History

DE:2PQ earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.12-0.28――
Nov 05, 20262026 (Q3)-0.16-0.220.11-301.63% (-0.33)
Aug 06, 20262026 (Q2)-0.32-0.64-0.06-1033.33% (-0.59)
May 07, 20262026 (Q1)-0.26-0.33-0.15-115.29% (-0.18)
Feb 26, 20262025 (Q4)0.190.280.04675.00% (+0.24)
Nov 06, 20252025 (Q3)0.060.110.0836.67% (+0.03)
Aug 07, 20252025 (Q2)-0.05-0.06-0.1251.54% (+0.06)
May 08, 20252025 (Q1)-0.03-0.15-0.01-1033.33% (-0.14)
Feb 27, 20252024 (Q4)-0.010.040.02110.53% (+0.02)
Nov 12, 20242024 (Q3)-0.020.080.03150.00% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed